Delivery Order SPE2DB20D1100-SPE2DB25FA5K2
Award Date
2/10/25
Potential Completion Date
3/4/25
Potential Value
$120K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $60,096.40 firm fixed-price delivery order contract is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 18, 2025 and was awarded on January 27, 2025. This delivery order is part of a larger $999,999,999 Indefinite Delivery Contract...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract is a Firm Fixed Price Delivery Order with a period of performance ending on January 28, 2025. The contract was not set aside for any specific business category. In addition to this delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $47,834.16 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of December 16, 2024 and does not include any set-aside requirements, indicating open competition. AmerisourceBergen holds a significant $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $48,077.16, is a delivery order for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 28, 2025 and is a firm fixed-price arrangement. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a for-profit pharmaceutical distribution company. The $11,559.04 firm fixed price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. The award is not associated with any set-aside program. AmerisourceBergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, holds an Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $48,077.16 firm fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication. The contract has an ultimate completion date of February 21, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of OCREVUS (ocrelizumab) 300 mg/10 ml vials. The $46,236.16 firm fixed-price delivery order has an ultimate completion date of October 18, 2024. The award is not associated with a set-aside program. This contract is likely part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corporation's Corporate Office Division. The contract, valued at up to $115,590.40, is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. This is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distribution company. The $46,236.16 firm-fixed-price delivery order is for the supply of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty pharmaceutical product. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. This single-award IDC serves...
This federal contract award, valued at $12,019.28, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of OCREVUS 300 MG/10 ML VIAL 10ML, a specialty medication, with a period of performance through February 13, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...